Thomas Clark Gamblin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1235701/publications.pdf

Version: 2024-02-01

147 papers 3,222 citations

32 h-index 189892 50 g-index

149 all docs 149
docs citations

149 times ranked 4834 citing authors

#	Article	IF	CITATIONS
1	Comprehensive genomic profiling (CGP) of fibrolamellar oncocytic hepatoma (FLO) and conventional hepatocellular carcinomas (HCC): An observational study Journal of Clinical Oncology, 2022, 40, 474-474.	1.6	O
2	Conversion to resection post radioembolization in patients with HCC: recommendations from a multidisciplinary working group. Hpb, 2022, 24, 1007-1018.	0.3	8
3	Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2022, 157, 590.	4.3	25
4	Palliative Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Is It Safe and Effective?. Journal of Surgical Research, 2022, 278, 31-38.	1.6	1
5	Impact of resection margin on outcomes in highâ€grade soft tissue sarcomas of the extremity—A USSC analysis. Journal of Surgical Oncology, 2021, 123, 479-488.	1.7	3
6	The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative. Journal of Gastrointestinal Surgery, 2021, 25, 2908-2919.	1.7	4
7	Two-Stage Hepatectomy for Bilateral Colorectal Liver Metastases: A Multi-institutional Analysis. Annals of Surgical Oncology, 2021, 28, 1457-1465.	1.5	17
8	Molecular and Genetic Markers in Appendiceal Mucinous Tumors: A Systematic Review. Annals of Surgical Oncology, 2020, 27, 85-97.	1.5	22
9	Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 134-146.	1.5	14
10	Trends in the Use of Adjuvant Chemotherapy for High-Grade Truncal and Extremity Soft Tissue Sarcomas. Journal of Surgical Research, 2020, 245, 577-586.	1.6	3
11	Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 156-164.	1.5	13
12	Primary Liver Cancer: An NCDB Analysis of Overall Survival and Margins After Hepatectomy. Annals of Surgical Oncology, 2020, 27, 1156-1163.	1.5	7
13	High neutrophil-lymphocyte ratio is not independently associated with worse survival or recurrence in patients with extremity soft tissue sarcoma. Surgery, 2020, 168, 760-767.	1.9	2
14	A closer look at the natural history and recurrence patterns of high-grade truncal/extremity leiomyosarcomas: A multi-institutional analysis from the US Sarcoma Collaborative. Surgical Oncology, 2020, 34, 292-297.	1.6	2
15	Comparison of overall survival in gallbladder carcinoma at academic versus community cancer centers: An analysis of the National Cancer Data Base. Journal of Surgical Oncology, 2020, 122, 176-182.	1.7	7
16	Outcomes of palliativeâ€intent surgery in retroperitoneal sarcomaâ€"Results from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2020, 121, 1140-1147.	1.7	7
17	Outcomes of Elderly Patients Undergoing Curative Resection for Retroperitoneal Sarcomas: Analysis From the US Sarcoma Collaborative. Journal of Surgical Research, 2019, 233, 154-162.	1.6	6
18	Facility Type is Associated with Margin Status and Overall Survival of Patients with Resected Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2019, 26, 4091-4099.	1.5	31

#	Article	IF	Citations
19	Lung Surveillance Strategy for High-Grade Soft Tissue Sarcomas: Chest X-Ray or CT Scan?. Journal of the American College of Surgeons, 2019, 229, 449-457.	0.5	14
20	Recurrence patterns after resection of retroperitoneal sarcomas: An eightâ€institution study from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2019, 120, 340-347.	1.7	29
21	Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival. Cancer Medicine, 2019, 8, 928-938.	2.8	16
22	It Is Time. Annals of Surgical Oncology, 2019, 26, 1963-1966.	1.5	0
23	Xanthohumol increases death receptor 5 expression and enhances apoptosis with the TNF-related apoptosis-inducing ligand in neuroblastoma cell lines. PLoS ONE, 2019, 14, e0213776.	2.5	19
24	Survival after Resection of Multiple Tumor Foci of Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2019, 23, 2239-2246.	1.7	32
25	RAS Mutation Status Confers Prognostic Relevance in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer. Journal of Surgical Research, 2019, 240, 130-135.	1.6	13
26	Surgical resectability of multisite metastatic colorectal cancer: Pushing the limits while appropriately selecting patients. Journal of Surgical Oncology, 2019, 119, 623-628.	1.7	4
27	Molecular Characteristics of Biliary Tract and Primary Liver Tumors. Surgical Oncology Clinics of North America, 2019, 28, 685-693.	1.5	6
28	Hepatobiliary Malignancies: The Changing Landscape. Surgical Oncology Clinics of North America, 2019, 28, xv.	1.5	0
29	Effect of Donor Race-Matching on Overall Survival for African-American Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Journal of the American College of Surgeons, 2019, 228, 245-254.	0.5	8
30	Elective Regional Therapy Treatment for Hepatic Adenoma. Annals of Surgical Oncology, 2019, 26, 125-130.	1.5	10
31	Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 236.	7.1	36
32	Ablation approach for primary liver tumors: Periâ€operative outcomes. Journal of Surgical Oncology, 2018, 117, 1493-1499.	1.7	5
33	Minimally invasive hepatectomy conversions: an analysis of risk factors and outcomes. Hpb, 2018, 20, 132-139.	0.3	23
34	Gallbladder carcinoma: An analysis of the national cancer data base to examine hispanic influence. Journal of Surgical Oncology, 2018, 117, 1664-1671.	1.7	4
35	Overall survival after resection of retroperitoneal sarcoma at academic cancer centers versus community cancer centers: An analysis of the National Cancer Data Base. Surgery, 2018, 163, 318-323.	1.9	29
36	Together We Make a Difference. Annals of Surgical Oncology, 2018, 25, 1794-1796.	1.5	0

#	Article	IF	CITATIONS
37	The effect of prior upper abdominal surgery on outcomes after liver transplantation for hepatocellular carcinoma: An analysis of the database of the organ procurement transplant network. Surgery, 2018, 163, 1028-1034.	1.9	8
38	Perioperative chemotherapy is not associated with improved survival in high-grade truncal sarcoma. Journal of Surgical Research, 2018, 231, 248-256.	1.6	2
39	Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro. BMC Cancer, 2018, 18, 560.	2.6	33
40	Studying a Rare Disease Using Multi-Institutional Research Collaborations vs Big Data: Where Lies the Truth?. Journal of the American College of Surgeons, 2018, 227, 357-366e3.	0.5	13
41	The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma. Surgery, 2018, 164, 411-418.	1.9	38
42	Factors associated with palliative care use in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Journal of Surgical Research, 2017, 211, 79-86.	1.6	9
43	The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients—A multiâ€institutional analysis. Journal of Surgical Oncology, 2017, 115, 312-318.	1.7	46
44	External radiation or ablation for solitary hepatocellular carcinoma: A survival analysis of the SEER database. Journal of Surgical Oncology, 2017, 116, 307-312.	1.7	21
45	Suberoylanilide hydroxamic Acid, a histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines. American Journal of Surgery, 2017, 213, 645-651.	1.8	9
46	Performance of prognostic scores and staging systems in predicting longâ€ŧerm survival outcomes after surgery for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2017, 116, 1085-1095.	1.7	42
47	The prognostic utility of baseline alphaâ€fetoprotein for hepatocellular carcinoma patients. Journal of Surgical Oncology, 2017, 116, 831-840.	1.7	27
48	Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. Hpb, 2017, 19, 659-666.	0.3	84
49	Ushering in a New Era for Regional Therapies. Annals of Surgical Oncology, 2017, 24, 868-869.	1.5	O
50	Morbidity of curative cancer surgery and suicide risk. Psycho-Oncology, 2017, 26, 1792-1798.	2.3	10
51	Palliative interventions for hepatocellular carcinoma patients: analysis of the National Cancer Database. Annals of Palliative Medicine, 2017, 6, 26-35.	1.2	15
52	Antiproliferative and apoptotic effects of xanthohumol in cholangiocarcinoma. Oncotarget, 2017, 8, 88069-88078.	1.8	19
53	Two-stage hepatectomy for colorectal liver metastases: A multi-institutional retrospective review Journal of Clinical Oncology, 2017, 35, 351-351.	1.6	0
54	Cost effectiveness of maintenance bevacizumab in patients with metastatic colorectal cancer Journal of Clinical Oncology, 2017, 35, 718-718.	1.6	2

#	Article	IF	Citations
55	The utilization of palliative radiation therapy to the liver for hepatocellular carcinoma Journal of Clinical Oncology, 2017, 35, 474-474.	1.6	1
56	Does hepatectomy approach influence transfusion? An analysis of the National Surgical Quality Improvement Program database Journal of Clinical Oncology, 2017, 35, 447-447.	1.6	0
57	Effect of extended postoperative recovery on long-term oncological outcomes Journal of Clinical Oncology, 2017, 35, 765-765.	1.6	O
58	Minimally invasive hepatectomy conversions: An analysis of outcomes Journal of Clinical Oncology, 2017, 35, 430-430.	1.6	0
59	Single-stage resection and microwave ablation for bilobar colorectal liver metastases. British Journal of Surgery, 2016, 103, 1048-1054.	0.3	31
60	A multi-institutional analysis of elderly patients undergoing a liver resection for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2016, 113, 420-426.	1.7	37
61	Neoadjuvant radiotherapy for retroperitoneal sarcoma: A systematic review. Journal of Surgical Oncology, 2016, 113, 628-634.	1.7	24
62	A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis. Journal of Gastrointestinal Surgery, 2016, 20, 1098-1105.	1.7	33
63	Defining when to offer operative treatment for intrahepatic cholangiocarcinoma: A regret-based decision curves analysis. Surgery, 2016, 160, 106-117.	1.9	23
64	The role of liver-directed surgery in patients with hepatic metastasis from primary breast cancer: a multi-institutional analysis. Hpb, 2016, 18, 700-705.	0.3	46
65	Is Radiotherapy Warranted Following Intrahepatic Cholangiocarcinoma Resection? The Impact of Surgical Margins and Lymph Node Status on Survival. Annals of Surgical Oncology, 2016, 23, 912-920.	1.5	28
66	Is longâ€term survival possible after marginâ€positive resection of retroperitoneal sarcoma (RPS)?. Journal of Surgical Oncology, 2016, 113, 823-827.	1.7	12
67	Age-based disparities in treatment and outcomes of retroperitoneal rhabdomyosarcoma. International Journal of Clinical Oncology, 2016, 21, 602-608.	2.2	2
68	Role of Akt inhibition on Notch1 expression in hepatocellular carcinoma: potential role for dual targeted therapy. American Journal of Surgery, 2016, 211, 755-760.	1.8	7
69	Regional Therapies for Advanced Cancer: Update for 2016. Annals of Surgical Oncology, 2016, 23, 1452-1453.	1.5	0
70	Cholangiocarcinoma risk factors and the potential role of aspirin. Hepatology, 2016, 64, 708-710.	7.3	10
71	The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. Annals of Surgical Oncology, 2016, 23, 290-296.	1.5	80
72	A literature review of radiological findings to guide the diagnosis of gallbladder adenomyomatosis. Hpb, 2016, 18, 129-135.	0.3	29

#	Article	IF	Citations
73	ReCAP: Cost Differential of Chemotherapy for Solid Tumors. Journal of Oncology Practice, 2016, 12, 251-251.	2.5	12
74	Hepatic Perfusion Therapy. Surgical Clinics of North America, 2016, 96, 357-368.	1.5	1
7 5	Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options. Journal of Surgical Oncology, 2016, 113, 55-61.	1.7	34
76	Conditional Survival as a Patient Centered Metric for Patients with Appendiceal Adenocarcinoma. Annals of Surgical Oncology, 2016, 23, 2295-2301.	1.5	4
77	Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection. Annals of Surgical Oncology, 2016, 23, 235-243.	1.5	195
78	Conditional probability of survival in gallbladder carcinoma as a prognostic tool for long term survivors Journal of Clinical Oncology, 2016, 34, 455-455.	1.6	0
79	Palliative care for hepatocellular carcinoma: Analysis of the National Cancer Data Base Journal of Clinical Oncology, 2016, 34, 390-390.	1.6	O
80	Chasing the proverbial unicorn of relative value units (RVU) and block time Journal of Clinical Oncology, 2016, 34, 660-660.	1.6	0
81	Overall survival and resection margin after hepatectomy for intrahepatic cholangiocarcinoma at academic cancer centers versus community cancer centers Journal of Clinical Oncology, 2016, 34, 339-339.	1.6	0
82	A multi-institutional analysis of duodenal neuroendocrine tumors: Tumor biology rather than extent of resection to dictate prognosis Journal of Clinical Oncology, 2016, 34, 255-255.	1.6	1
83	Conversion to resectability in unresectable metastatic colorectal cancer chemotherapy (mCRC) trials Journal of Clinical Oncology, 2016, 34, 641-641.	1.6	O
84	Radiotherapy for intrahepatic cholangiocarcinoma: An analysis of the National Cancer Database Journal of Clinical Oncology, 2016, 34, 379-379.	1.6	0
85	Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression. Hpb, 2015, 17, 770-776.	0.3	27
86	Surgical resection versus ablation for hepatocellular carcinoma â‰ Â 3Âcm: a population-based analysis. Hpb, 2015, 17, 896-901.	0.3	34
87	Can hepatic resection provide a longâ€term cure for patients with intrahepatic cholangiocarcinoma?. Cancer, 2015, 121, 3998-4006.	4.1	131
88	Safety and efficacy of transarterial chemoembolization in patients with transjugular intrahepatic portosystemic shunts. Hpb, 2015, 17, 707-712.	0.3	14
89	Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy. Hpb, 2015, 17, 1119-1123.	0.3	10
90	Impact of complications on longâ€term survival after resection of intrahepatic cholangiocarcinoma. Cancer, 2015, 121, 2730-2739.	4.1	61

#	Article	IF	CITATIONS
91	Xanthohumol Inhibits Notch Signaling and Induces Apoptosis in Hepatocellular Carcinoma. PLoS ONE, 2015, 10, e0127464.	2.5	46
92	Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis. PLoS ONE, 2015, 10, e0139940.	2.5	43
93	Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2015, 111, 213-220.	1.7	146
94	Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis. Cancer Cell International, 2015, 15, 13.	4.1	23
95	Presentation and Clinical Outcomes of Choledochal Cysts in Children and Adults. JAMA Surgery, 2015, 150, 577.	4.3	98
96	Curcumin-mediated regulation of Notch1/hairy and enhancer of split-1/survivin: molecular targeting in cholangiocarcinoma. Journal of Surgical Research, 2015, 198, 434-440.	1.6	25
97	Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. Cancer Biology and Therapy, 2015, 16, 764-769.	3.4	16
98	Minimally invasive gastrectomy for cancer: current utilization in US academic medical centers. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 3768-3775.	2.4	22
99	Conditional Probability of Long-term Survival After Liver Resection for Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2015, 150, 538.	4.3	91
100	Conditional Disease-Free Survival After Surgical Resection of Gastrointestinal Stromal Tumors. JAMA Surgery, 2015, 150, 299.	4.3	52
101	The Impact of Surgical Margin Status on Long-Term Outcome After Resection for Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2015, 22, 4020-4028.	1.5	126
102	Xanthohumol-Mediated Suppression of Notch1 Signaling Is Associated with Antitumor Activity in Human Pancreatic Cancer Cells. Molecular Cancer Therapeutics, 2015, 14, 1395-1403.	4.1	44
103	Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2015, 22, 3716-3723.	1.5	83
104	Intrahepatic Cholangiocarcinoma: Prognosis of Patients Who Did Not Undergo Lymphadenectomy. Journal of the American College of Surgeons, 2015, 221, 1031-1040e4.	0.5	61
105	Palliative Care Training in Surgical Oncology and Hepatobiliary Fellowships: A National Survey of Program Directors. Annals of Surgical Oncology, 2015, 22, 1181-1186.	1.5	23
106	Transarterial Chemoembolization for Primary Liver Malignancies and Colorectal Liver Metastasis. Surgical Oncology Clinics of North America, 2015, 24, 149-166.	1.5	15
107	Comprehensive multiplatform biomarker analysis of 313 hepatocellular carcinoma to identify potential therapeutic options Journal of Clinical Oncology, 2015, 33, 283-283.	1.6	0
108	Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative intent surgical resection Journal of Clinical Oncology, 2015, 33, 349-349.	1.6	0

#	Article	IF	Citations
109	Chemotherapy for surgically resected intrahepatic cholangiocarcinoma: Influence of lymph node status on treatment efficacy Journal of Clinical Oncology, 2015, 33, 353-353.	1.6	O
110	Molecular characterization of 350 hepatocellular carcinomas to identify biomarker aberrations with potential novel therapeutic options Journal of Clinical Oncology, 2015, 33, 4086-4086.	1.6	0
111	Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer Biology and Therapy, 2014, 15, 510-515.	3.4	34
112	Multi-institutional analysis of recurrence and survival after hepatectomy for fibrolamellar carcinoma. Journal of Surgical Oncology, 2014, 110, 412-415.	1.7	27
113	An acute rise in intraluminal pressure shifts the mediator of flow-mediated dilation from nitric oxide to hydrogen peroxide in human arterioles. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H1587-H1593.	3.2	54
114	Palliation. Surgical Oncology Clinics of North America, 2014, 23, 383-397.	1.5	8
115	Effect of the experience of surgical chairpersons on departmental National Institutes of Health funding. Journal of Surgical Research, 2014, 192, 293-297.	1.6	3
116	Neutrophilâ€toâ€lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma: A Western perspective. Journal of Surgical Oncology, 2014, 109, 95-97.	1.7	36
117	Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. European Journal of Cancer, 2014, 50, 1747-1757.	2.8	82
118	Molecular profiling in gastric cancer: Examining potential targets for chemotherapy. Journal of Surgical Oncology, 2014, 110, 302-306.	1.7	8
119	Surgical Management of Advanced Gastrointestinal Stromal Tumors: An International Multi-Institutional Analysis of 158 Patients. Journal of the American College of Surgeons, 2014, 219, 439-449.	0.5	28
120	Immunohistochemistry $\tilde{A}^{\xi}\hat{a}$, $\neg\hat{a}\in\infty$ Microarray Analysis of Patients with Peritoneal Metastases of Appendiceal or Colorectal Origin. Frontiers in Surgery, 2014, 1, 50.	1.4	9
121	Mismatch repair protein loss and microsatellite instability in cholangiocarcinoma Journal of Clinical Oncology, 2014, 32, 237-237.	1.6	6
122	Neoadjuvant therapy for pancreatic cancer in patients older than age 75 Journal of Clinical Oncology, 2014, 32, 287-287.	1.6	8
123	Genomic profiling of intrahepatic cholangiocarcinoma: Refining prognostic determinants and identifying therapeutic targets Journal of Clinical Oncology, 2014, 32, 210-210.	1.6	2
124	Molecular profiling in gastric cancer: Examining potential targets for chemotherapy Journal of Clinical Oncology, 2014, 32, 131-131.	1.6	0
125	Cost-effectiveness of routine laparoscopic ultrasound for the assessment of resectability of gallbladder cancer Journal of Clinical Oncology, 2014, 32, 272-272.	1.6	0
126	Open versus minimally invasive management of gastric GIST: An international multi-institutional analysis of short- and long-term outcomes Journal of Clinical Oncology, 2014, 32, 85-85.	1.6	0

#	Article	IF	CITATIONS
127	Cost differential among systemic therapies for colon cancer Journal of Clinical Oncology, 2014, 32, 583-583.	1.6	0
128	Tumor profiling of 1,306 gastric and esophageal carcinomas and different treatment options Journal of Clinical Oncology, 2014, 32, 4017-4017.	1.6	0
129	Cost differential among systemic therapies for breast, bladder, lung, and colon cancer Journal of Clinical Oncology, 2014, 32, e17541-e17541.	1.6	0
130	Recent advances in systemic therapies and radiotherapy for gallbladder cancer. Surgical Oncology, 2013, 22, 61-67.	1.6	35
131	Regional Therapies for Cancer. Annals of Surgical Oncology, 2013, 20, 1053-1055.	1.5	0
132	Modern perspectives on factors predisposing to the development of gallbladder cancer. Hpb, 2013, 15, 839-844.	0.3	59
133	Key Factors Influencing Prognosis in Relation to Gallbladder Cancer. Digestive Diseases and Sciences, 2013, 58, 2455-2462.	2.3	24
134	Transplantation versus resection for patients with combined hepatocellular carcinoma–cholangiocarcinoma. Journal of Surgical Oncology, 2013, 107, 608-612.	1.7	80
135	Management of primary hepatopancreatobiliary small cell carcinoma. Journal of Surgical Oncology, 2013, 107, 692-695.	1.7	14
136	Analysis of toxicity and outcomes in patients undergoing hyperthermic isolated hepatic perfusion with melphalan for metastatic melanoma to the liver Journal of Clinical Oncology, 2013, 31, 178-178.	1.6	0
137	Ablation for hepatocellular carcinoma: Validating the 3-cm breakpoint Journal of Clinical Oncology, 2013, 31, 277-277.	1.6	0
138	Microwave ablation for hepatic malignancies: A multi-institutional analysis Journal of Clinical Oncology, 2013, 31, 218-218.	1.6	1
139	The course of depression, inflammation in the serum and tumor microenvironment, and survival in the context of advanced cancer Journal of Clinical Oncology, 2013, 31, 9507-9507.	1.6	0
140	Economic model of observation versus immediate resection of hepatic adenomas. Journal of Surgical Oncology, 2012, 106, 491-497.	1.7	0
141	Concepts of Regional Therapies for Advanced Malignancy. Annals of Surgical Oncology, 2012, 19, 1371-1372.	1.5	1
142	Does a common vascular origin confer similar prognosis to malignant tumors of the liver?. Journal of Clinical Oncology, 2012, 30, 186-186.	1.6	0
143	Is survival from resection of pancreatic adenocarcinoma with major arterial involvement any different than venous/minor arterial resection?. Journal of Clinical Oncology, 2012, 30, 310-310.	1.6	0
144	Are we justified in excluding combined hepatocellular-cholangiocarcinoma from transplantation?. Journal of Clinical Oncology, 2012, 30, 256-256.	1.6	0

#	Article	IF	CITATIONS
145	Radiofrequency Ablation of Neuroendocrine Hepatic Metastasis. Surgical Oncology Clinics of North America, 2011, 20, 273-279.	1.5	29
146	Safety of Liver Resection in the Elderly: How Important Is Age?. Annals of Surgical Oncology, 2011, 18, 1088-1095.	1.5	54
147	Hepatic Resection Nomenclature and Techniques. Surgical Clinics of North America, 2010, 90, 737-748.	1.5	19